Fospropofol is a prodrug of propofol which hydrolyzes in the body by alkaline phosphatase to liberate propofol. Propofol liberated from fospropofol has unique pharmacological properties. Fospropofol in doses of 6.5 or 8 mg/kg, is effective and well tolerated for the sedation of patients undergoing colonoscopy, flexible bronchoscopy. When administered intravenously by a dentist anesthesiologist at the indicated dose, it appearsed to be a safe, well-tolerated alternative to midazolam for intravenous moderate sedation during minor oral surgery procedures. In addition, fospropofol provides safe and effective sedation, rapid time to full alert, and high satisfaction in the elderly subset undergoing flexible bronchoscopy, which is comparable with outcomes in younger patients. Study suggested that fospropofol. administered in an infusion/bolus regimen, be tolerable and effective for short-term induction and maintenance of sedation in intensive care unit patients. Fospropofol also could be used to provide general anesthesia in patients undergoing coronary artery bypass graft surgery.

OBJECTIVETo study the effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice.

METHODSMetastatic model was established by orthotopic implantation of histologically intact human tumor tissue into the gastric wall of SCID mice. Forty-eight mice were randomly divided into four groups, and saline, 5-FU, SU6668, and 5-FU plus SU6668 were administered by i.p. every day for 6 weeks after tumor implantation. The mice were killed and tumor weight, tumor inhibition rate, intratumoral microvessel density(MVD), apoptotic index(AI) and metastasis inhibition were evaluated.

RESULTSCompared with the control, tumor growth was significantly inhibited in mice treated respectively with 5-FU, SU6668 and 5-FU plus SU6668 with inhibition rates of 47.5%, 64.1% and 69.2% respectively. Decreased MVD and increased AI were noted in the mice treated with SU6668 and 5-FU plus SU6668. The incidences of liver and peritoneal metastases was significantly inhibited and decreased to 62.5%, 69.9% in SU6668 group, and 74.9%, 90% in 5-FU plus SU6668 group. The growth and metastasis of human gastric cancer implanted in SCID mice were significantly inhibited in SU6668 group and combined group, especially in combined group.

CONCLUSIONAngiogenesis inhibitor SU6668 has a strong inhibitory effect on tumor growth and metastasis of human gastric cancer transplanted in SCID mice, and has synergistic effect combined with cytotoxic agents.

Angiogenesis Inhibitors ; pharmacology ; therapeutic use ; Animals ; Apoptosis ; drug effects ; Cell Line, Tumor ; Drug Synergism ; Fluorouracil ; pharmacology ; therapeutic use ; Humans ; Indoles ; pharmacology ; therapeutic use ; Liver Neoplasms ; prevention & control ; secondary ; Male ; Mice ; Mice, SCID ; Neoplasm Transplantation ; Neoplasms, Experimental ; Neovascularization, Pathologic ; drug therapy ; Pyrroles ; pharmacology ; therapeutic use ; Stomach Neoplasms ; drug therapy ; pathology

OBJECTIVETo investigate the differential gene expression profile from patients with Bardet-Biedl syndrome (BBS) by oligonucleotide microarray technique.

METHODSTotal RNA of 3 probands with BBS and 4 healthy siblings were isolated from peripheral blood mononuclear cells and reverse-transcribed to cDNAs. Then the cDNAs were subjected for microarray screening with Affymetrix U133 Plus 2.0 array. Genechip scanner was applied to screen the hybridization signals. Genes differentially expressed between the BBS probands and controls were identified by using GCOS1.4 software with the standard of two-fold change (P<0.05) of expression.

RESULTSFifteen genes were up-regulated 2 or more fold and another 15 genes were down-regulated 2 or more fold in the BBS patients, among them 12 genes were related to signaling pathway and cell cycle by Gene Ontology (GO) analysis.

CONCLUSIONThe differentially expressed genes identified may correlate with the function or structure of cilia. Their roles in the BBS genesis need to be further studied.

Adult ; Bardet-Biedl Syndrome ; genetics ; metabolism ; Cells, Cultured ; Female ; Gene Expression Profiling ; Gene Expression Regulation ; Humans ; Leukocytes, Mononuclear ; metabolism ; Male ; Oligonucleotide Array Sequence Analysis ; Siblings

Objective: To study the safety and efficacy of Bushen Daozhuo Granules (BDG) in the treatment of type Ⅲ prostatitis. METHODS: This multicenter randomized controlled clinical trial included 478 patients with type Ⅲ prostatitis, 290 in the trial group and 188 as controls, the former treated with BDG at 200 ml bid and the latter with tamsulosin hydrochloride sustainedrelease capsules at 0.2 mg qd, both for 4 weeks. Before treatment, after 4 weeks of medication, and at 4 weeks after drug withdrawal, we obtained the NIH Chronic Prostatitis Symptom Index (NIHCPSI) scores and compared the safety and effectiveness rate between the two groups of patients. RESULTS: Compared with the baseline, the NIHCPSI score was markedly decreased in the control group after 4 weeks of medication (21.42 ± 4.02 vs 15.67 ± 3.65, P < 0.05) but showed no statistically significant difference from that at 4 weeks after drug withdrawal (19.03 ± 3.86) (P>0.05), while the NIHCPSI score in the trial group was remarkably lower than the baseline both after 4 weeks of medication and at 4 weeks after drug withdrawal (10.92 ± 2.06 and 12.91 ± 2.64 vs 21.58 ± 3.67, P < 0.05). The trial group exhibited both a higher rate of total effectiveness and safety than the control (P < 0.05). CONCLUSIONS BDG is safe and effective for the treatment of type Ⅲ prostatitis.
Capsules ; Chronic Disease ; Delayed-Action Preparations ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Humans ; Male ; Prostatitis ; drug therapy ; pathology ; Sulfonamides ; adverse effects ; therapeutic use ; Tamsulosin ; Treatment Outcome ; Urological Agents ; adverse effects ; therapeutic use